Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.03 EPS

Xeris Biopharma (NASDAQ:XERS) announced its quarterly earnings results on Thursday. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03, FiscalAI reports. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Xeris reported third-quarter revenue of $107.2 million, up 44% year over year, and raised 2026 revenue guidance to $395 million–$405 million. Management also raised its 2030 revenue outlook from $750 million to more than $1 billion.
• Recorlev revenue nearly doubled year over year to $71.5 million, with record referrals and patient starts following the expanded commercial team’s ramp-up. Management expects momentum to continue, supported by broader screening for hypercortisolism, though access still typically requires prior authorization.
• Gvoke prescriptions rose 5% year over year, but net revenue fell to $21.7 million from $25.2 million a year earlier because of a one-time $4 million Medicaid gross-to-net adjustment. Management said demand improved through the quarter and expects the brand to return to growth.
• KEVEYIS generated $13 million in revenue, its fourth consecutive quarter of year-over-year growth, and received a U.S. patent extending protection through at least 2043. The company plans additional investment to find and support more patients.
• Xeris remains on track to start the pivotal Phase III Cornerstone study of XP-8121 by year-end, with topline results expected in late 2028 and a potential 2030 launch. Management cited peak sales potential of $1 billion–$3 billion, although the opportunity depends on successful clinical development.

Xeris Biopharma Stock Up 25.0%

Shares of NASDAQ:XERS traded up $2.62 during trading on Thursday, hitting $13.08. 12,595,769 shares of the company’s stock traded hands, compared to its average volume of 2,079,860. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $13.74. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -118.91 and a beta of 0.61. The company has a 50-day moving average price of $9.40 and a 200-day moving average price of $7.55.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Xeris reported third-quarter adjusted earnings of $0.06 per share, above analysts’ consensus of $0.03, while revenue of $107.23 million also topped the roughly $101.68 million estimate. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: CEO comments indicated that Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected, strengthening the growth outlook for the company’s commercial portfolio. CEO sees Recorlev nearing $1B in annual sales earlier than expected
• Neutral Sentiment: Xeris updated its FY 2030 earnings guidance, but the provided information does not include the new figures, making the impact difficult to assess.
• Negative Sentiment: Several insiders reported sales totaling 45,000 shares at $10.23 per share. The trades were made under pre-arranged Rule 10b5-1 plans, and the sellers retained substantial holdings, which may temper concern about the transactions.

Wall Street Analysts Forecast Growth

Several brokerages have commented on XERS. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Barclays increased their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Leerink Partners boosted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.20.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $51,150.00. Following the transaction, the insider owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This represents a 2.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 148,332 shares of company stock worth $1,409,221. 4.35% of the stock is owned by company insiders.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.